Liraglutide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 7 Jan 2011: Trial registered, NCT01272219
  2. 1 Jun 2011: Trial started, NCT01272219

The trials

NCT00422058: The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

State
Completed
Phase
Phase 2
People
564 taking part
Started
10 Jan 2007
Primary completion
13 Sep 2007
Arms
Lira 1.2 mg/Lira 3.0 mg, Lira 1.8 mg/Lira 3.0 mg, Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg
Results
Posted on the registry
  1. 10 Jan 2007: Trial started
  2. 15 Jan 2007: Trial registered
  3. 30 Apr 2009: Trial completed
  4. 28 Oct 2010: Trial results posted

NCT01272219: Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

State
Completed
Phase
Phase 3
People
3,731 taking part
Started
1 Jun 2011
Primary completion
18 Mar 2013
Arms
Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68), Liraglutide 3.0mg, Pre-diabetes
Results
Posted on the registry
  1. 7 Jan 2011: Trial registered
  2. 1 Jun 2011: Trial started
  3. 9 Feb 2015: Trial results posted
  4. 2 Mar 2015: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Saxenda, Victoza, XULTOPHY 100/3.6 COMPONENT LIRAGLUTIDE.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.